<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85065487045</prism:url><dc:identifier>SCOPUS_ID:85065487045</dc:identifier><eid>2-s2.0-85065487045</eid><prism:doi>10.3389/fphar.2019.00008</prism:doi><article-number>00008</article-number><dc:title>Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson's disease</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>1</citedby-count><prism:publicationName>Frontiers in Pharmacology</prism:publicationName><dc:publisher>Frontiers Media S.A.info@frontiersin.org</dc:publisher><source-id>21100214102</source-id><prism:issn>16639812</prism:issn><prism:volume>9</prism:volume><prism:issueIdentifier>JAN</prism:issueIdentifier><prism:coverDate>2019-01-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="57193522851"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Redenšek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57193522851</author-url><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>© 2007 - 2019 Frontiers Media S.A. All Rights Reserved.</publishercopyright><ce:para>Dopaminergic pathway is the most disrupted pathway in the pathogenesis of Parkinson's disease. Several studies reported associations of dopaminergic genes with the occurrence of adverse events of dopaminergic treatment. However, none of these studies adopted a pathway based approach. The aim of this study was to comprehensively evaluate the influence of selected single nucleotide polymorphisms of key dopaminergic pathway genes on the occurrence of motor and non-motor adverse events of dopaminergic treatment in Parkinson's disease. In total, 231 Parkinson's disease patients were enrolled. Demographic and clinical data were collected. Genotyping was performed for 16 single nucleotide polymorphisms from key dopaminergic pathway genes. Logistic and Cox regression analyses were used for evaluation. Results were adjusted for significant clinical data. We observed that carriers of at least one COMT rs165815 C allele had lower odds for developing visual hallucinations (OR = 0.34; 95% CI = 0.16-0.72; p = 0.004), while carriers of at least one DRD3 rs6280 C allele and CC homozygotes had higher odds for this adverse event (OR = 1.88; 95% CI = 1.00-3.54; p = 0.049 and OR = 3.31; 95% CI = 1.37-8.03; p = 0.008, respectively). Carriers of at least one DDC rs921451 C allele and CT heterozygotes had higher odds for orthostatic hypotension (OR = 1.86; 95% CI = 1.07-3.23; p = 0.028 and OR = 2.30; 95% CI = 1.26-4.20; p = 0.007, respectively). Heterozygotes for DDC rs3837091 and SLC22A1 rs628031 AA carriers also had higher odds for orthostatic hypotension (OR = 1.94; 95% CI = 1.07 - 3.51; p = 0.028 and OR = 2.57; 95% CI = 1.11 - 5.95; p = 0.028, respectively). Carriers of the SLC22A1 rs628031 AA genotype had higher odds for peripheral edema and impulse control disorders (OR = 4.00; 95% CI = 1.62 - 9.88; p = 0.003 and OR = 3.16; 95% CI = 1.03 - 9.72; p = 0.045, respectively). Finally, heterozygotes for SLC22A1 rs628031 and carriers of at least one SLC22A1 rs628031 A allele had lower odds for dyskinesia (OR = 0.48; 95% CI = 0.24 - 0.98, p = 0.043 and OR = 0.48; 95% CI = 0.25 - 0.92; p = 0.027, respectively). Gene-gene interactions, more specifically DDC-COMT, SLC18A2-SV2C, and SLC18A2-SLC6A3, also significantly influenced the occurrence of some adverse events. Additionally, haplotypes of COMT and SLC6A3 were associated with the occurrence of visual hallucinations (AT vs. GC: OR = 0.34; 95% CI = 0.16 - 0.72; p = 0.005) and orthostatic hypotension (ATG vs. ACG: OR = 2.48; 95% CI: 1.01 - 6.07; p = 0.047), respectively. Pathway based approach allowed us to identify new potential candidates for predictive biomarkers of adverse events of dopaminergic treatment in Parkinson's disease, which could contribute to treatment personalization.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85065487045" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85065487045&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85065487045&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"><affilname>University of Ljubljana Faculty of Medicine</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"><affilname>Univerzitetni Klinični Center Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="57193522851"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Redenšek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57193522851</author-url><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"/></author><author seq="2" auid="6503981050"><ce:initials>D.</ce:initials><ce:indexed-name>Flisar D.</ce:indexed-name><ce:surname>Flisar</ce:surname><ce:given-name>Dušan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Flisar D.</ce:indexed-name><ce:surname>Flisar</ce:surname><ce:given-name>Dušan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6503981050</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="3" auid="36652889900"><ce:initials>M.</ce:initials><ce:indexed-name>Kojovic M.</ce:indexed-name><ce:surname>Kojovic</ce:surname><ce:given-name>Maja</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Kojovic M.</ce:indexed-name><ce:surname>Kojovic</ce:surname><ce:given-name>Maja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36652889900</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="4" auid="36544238400"><ce:initials>M.G.</ce:initials><ce:indexed-name>Kramberger M.G.</ce:indexed-name><ce:surname>Kramberger</ce:surname><ce:given-name>Milica Gregorič</ce:given-name><preferred-name><ce:initials>M.G.</ce:initials><ce:indexed-name>Kramberger M.</ce:indexed-name><ce:surname>Kramberger</ce:surname><ce:given-name>Milica Gregorič</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36544238400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="5" auid="36542322400"><ce:initials>D.</ce:initials><ce:indexed-name>Georgiev D.</ce:indexed-name><ce:surname>Georgiev</ce:surname><ce:given-name>Dejan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Georgiev D.</ce:indexed-name><ce:surname>Georgiev</ce:surname><ce:given-name>Dejan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36542322400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="6" auid="6603412901"><ce:initials>Z.</ce:initials><ce:indexed-name>Pirtosek Z.</ce:indexed-name><ce:surname>Pirtošek</ce:surname><ce:given-name>Zvezdan</ce:given-name><preferred-name><ce:initials>Z.</ce:initials><ce:indexed-name>Pirtošek Z.</ce:indexed-name><ce:surname>Pirtošek</ce:surname><ce:given-name>Zvezdan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6603412901</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="7" auid="7003908826"><ce:initials>M.</ce:initials><ce:indexed-name>Trost M.</ce:indexed-name><ce:surname>Trošt</ce:surname><ce:given-name>Maja</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Trošt M.</ce:indexed-name><ce:surname>Trošt</ce:surname><ce:given-name>Maja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7003908826</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="8" auid="6602823313"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name><preferred-name><ce:initials>V.</ce:initials><ce:indexed-name>Dolžan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6602823313</author-url><affiliation id="60021802" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021802"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Adverse events</author-keyword><author-keyword>Dopaminergic pathway</author-keyword><author-keyword>Genetic polymorphism</author-keyword><author-keyword>Parkinson's disease</author-keyword><author-keyword>Personalized medicine</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="3004" abbrev="PHAR">Pharmacology</subject-area><subject-area code="2736" abbrev="MEDI">Pharmacology (medical)</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2019-06-17T17:26:57.495Z</xocs:funding-addon-generated-timestamp><xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type><xocs:funding><xocs:funding-agency-matched-string>Slovenian Research Agency</xocs:funding-agency-matched-string><xocs:funding-id>P1-0170</xocs:funding-id><xocs:funding-id>ARRS</xocs:funding-id><xocs:funding-agency>Javna Agencija za Raziskovalno Dejavnost RS</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004329</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/3190538/</xocs:funding-agency-country></xocs:funding><xocs:funding-text>This study was funded by the Slovenian Research Agency (ARRS), grant number P1-0170 and grant for young researchers (SR).</xocs:funding-text></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered day="18" month="08" timestamp="2019-08-18T20:16:33.000033-04:00" year="2019"/><ait:date-sort day="01" month="01" year="2019"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2019 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:doi>10.3389/fphar.2019.00008</ce:doi><itemid idtype="PUI">627546250</itemid><itemid idtype="CAR-ID">917290747</itemid><itemid idtype="EMBASE">20190321399</itemid><itemid idtype="REAXYSCAR">20190888632</itemid><itemid idtype="RMC">2019138808</itemid><itemid idtype="SCOPUS">20191357203</itemid><itemid idtype="SCP">85065487045</itemid><itemid idtype="SGR">85065487045</itemid></itemidlist><history><date-created day="20" month="05" timestamp="BST 08:25:46" year="2019"/></history><dbcollection>EMBASE</dbcollection><dbcollection>REAXYSCAR</dbcollection><dbcollection>RMC</dbcollection><dbcollection>SCOPUS</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword xml:lang="eng">Adverse events</author-keyword><author-keyword xml:lang="eng">Dopaminergic pathway</author-keyword><author-keyword xml:lang="eng">Genetic polymorphism</author-keyword><author-keyword xml:lang="eng">Parkinson's disease</author-keyword><author-keyword xml:lang="eng">Personalized medicine</author-keyword></author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson's disease</titletext></citation-title><author-group><author auid="57193522851" seq="1" type="auth"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Redenšek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname><ce:given-name>Sara</ce:given-name></preferred-name></author><author auid="6602823313" seq="8" type="auth"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name><preferred-name><ce:initials>V.</ce:initials><ce:indexed-name>Dolžan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name></preferred-name></author><affiliation afid="60021802" country="svn" dptid="118365231"><organization>Pharmacogenetics Laboratory</organization><organization>Institute of Biochemistry</organization><organization>Faculty of Medicine</organization><organization>University of Ljubljana</organization><city>Ljubljana</city><affiliation-id afid="60021802" dptid="118365231"/><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="6503981050" seq="2" type="auth"><ce:initials>D.</ce:initials><ce:indexed-name>Flisar D.</ce:indexed-name><ce:surname>Flisar</ce:surname><ce:given-name>Dušan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Flisar D.</ce:indexed-name><ce:surname>Flisar</ce:surname><ce:given-name>Dušan</ce:given-name></preferred-name></author><author auid="36652889900" seq="3" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Kojovic M.</ce:indexed-name><ce:surname>Kojovic</ce:surname><ce:given-name>Maja</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Kojovic M.</ce:indexed-name><ce:surname>Kojovic</ce:surname><ce:given-name>Maja</ce:given-name></preferred-name></author><author auid="36544238400" seq="4" type="auth"><ce:initials>M.G.</ce:initials><ce:indexed-name>Kramberger M.G.</ce:indexed-name><ce:surname>Kramberger</ce:surname><ce:given-name>Milica Gregorič</ce:given-name><preferred-name><ce:initials>M.G.</ce:initials><ce:indexed-name>Kramberger M.</ce:indexed-name><ce:surname>Kramberger</ce:surname><ce:given-name>Milica Gregorič</ce:given-name></preferred-name></author><author auid="36542322400" seq="5" type="auth"><ce:initials>D.</ce:initials><ce:indexed-name>Georgiev D.</ce:indexed-name><ce:surname>Georgiev</ce:surname><ce:given-name>Dejan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Georgiev D.</ce:indexed-name><ce:surname>Georgiev</ce:surname><ce:given-name>Dejan</ce:given-name></preferred-name></author><author auid="6603412901" seq="6" type="auth"><ce:initials>Z.</ce:initials><ce:indexed-name>Pirtosek Z.</ce:indexed-name><ce:surname>Pirtošek</ce:surname><ce:given-name>Zvezdan</ce:given-name><preferred-name><ce:initials>Z.</ce:initials><ce:indexed-name>Pirtošek Z.</ce:indexed-name><ce:surname>Pirtošek</ce:surname><ce:given-name>Zvezdan</ce:given-name></preferred-name></author><author auid="7003908826" seq="7" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Trost M.</ce:indexed-name><ce:surname>Trošt</ce:surname><ce:given-name>Maja</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Trošt M.</ce:indexed-name><ce:surname>Trošt</ce:surname><ce:given-name>Maja</ce:given-name></preferred-name></author><affiliation afid="60021479" country="svn" dptid="113072952"><organization>Department of Neurology</organization><organization>University Medical Centre Ljubljana</organization><city>Ljubljana</city><affiliation-id afid="60021479" dptid="113072952"/><country>Slovenia</country></affiliation></author-group><correspondence><person><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname><ce:given-name>Vita</ce:given-name></person><affiliation country="svn"><organization>Pharmacogenetics Laboratory</organization><organization>Institute of Biochemistry</organization><organization>Faculty of Medicine</organization><organization>University of Ljubljana</organization><city>Ljubljana</city><country>Slovenia</country></affiliation></correspondence><grantlist complete="y"><grant-text xml:lang="eng">This study was funded by the Slovenian Research Agency (ARRS), grant number P1-0170 and grant for young researchers (SR).</grant-text></grantlist><abstracts><abstract original="y" xml:lang="eng"><publishercopyright>© 2007 - 2019 Frontiers Media S.A. All Rights Reserved.</publishercopyright><ce:para>Dopaminergic pathway is the most disrupted pathway in the pathogenesis of Parkinson's disease. Several studies reported associations of dopaminergic genes with the occurrence of adverse events of dopaminergic treatment. However, none of these studies adopted a pathway based approach. The aim of this study was to comprehensively evaluate the influence of selected single nucleotide polymorphisms of key dopaminergic pathway genes on the occurrence of motor and non-motor adverse events of dopaminergic treatment in Parkinson's disease. In total, 231 Parkinson's disease patients were enrolled. Demographic and clinical data were collected. Genotyping was performed for 16 single nucleotide polymorphisms from key dopaminergic pathway genes. Logistic and Cox regression analyses were used for evaluation. Results were adjusted for significant clinical data. We observed that carriers of at least one COMT rs165815 C allele had lower odds for developing visual hallucinations (OR = 0.34; 95% CI = 0.16-0.72; p = 0.004), while carriers of at least one DRD3 rs6280 C allele and CC homozygotes had higher odds for this adverse event (OR = 1.88; 95% CI = 1.00-3.54; p = 0.049 and OR = 3.31; 95% CI = 1.37-8.03; p = 0.008, respectively). Carriers of at least one DDC rs921451 C allele and CT heterozygotes had higher odds for orthostatic hypotension (OR = 1.86; 95% CI = 1.07-3.23; p = 0.028 and OR = 2.30; 95% CI = 1.26-4.20; p = 0.007, respectively). Heterozygotes for DDC rs3837091 and SLC22A1 rs628031 AA carriers also had higher odds for orthostatic hypotension (OR = 1.94; 95% CI = 1.07 - 3.51; p = 0.028 and OR = 2.57; 95% CI = 1.11 - 5.95; p = 0.028, respectively). Carriers of the SLC22A1 rs628031 AA genotype had higher odds for peripheral edema and impulse control disorders (OR = 4.00; 95% CI = 1.62 - 9.88; p = 0.003 and OR = 3.16; 95% CI = 1.03 - 9.72; p = 0.045, respectively). Finally, heterozygotes for SLC22A1 rs628031 and carriers of at least one SLC22A1 rs628031 A allele had lower odds for dyskinesia (OR = 0.48; 95% CI = 0.24 - 0.98, p = 0.043 and OR = 0.48; 95% CI = 0.25 - 0.92; p = 0.027, respectively). Gene-gene interactions, more specifically DDC-COMT, SLC18A2-SV2C, and SLC18A2-SLC6A3, also significantly influenced the occurrence of some adverse events. Additionally, haplotypes of COMT and SLC6A3 were associated with the occurrence of visual hallucinations (AT vs. GC: OR = 0.34; 95% CI = 0.16 - 0.72; p = 0.005) and orthostatic hypotension (ATG vs. ACG: OR = 2.48; 95% CI: 1.01 - 6.07; p = 0.047), respectively. Pathway based approach allowed us to identify new potential candidates for predictive biomarkers of adverse events of dopaminergic treatment in Parkinson's disease, which could contribute to treatment personalization.</ce:para></abstract></abstracts><source country="che" srcid="21100214102" type="j"><sourcetitle>Frontiers in Pharmacology</sourcetitle><sourcetitle-abbrev>Front. Pharmacol.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Frontiers in Pharmacology</translated-sourcetitle><issn type="electronic">16639812</issn><volisspag><voliss issue="JAN" volume="9"/></volisspag><article-number>00008</article-number><publicationyear first="2019"/><publicationdate><year>2019</year><date-text xfab-added="true">2019</date-text></publicationdate><website><ce:e-address type="email">http://www.frontiersin.org/Pharmacology</ce:e-address></website><publisher><publishername>Frontiers Media S.A.</publishername><ce:e-address type="email">info@frontiersin.org</ce:e-address></publisher></source><enhancement><classificationgroup><classifications type="EMCLASS"><classification> <classification-code>22</classification-code> <classification-description>Human Genetics</classification-description> </classification><classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification><classification> <classification-code>8</classification-code> <classification-description>Neurology and Neurosurgery</classification-description> </classification></classifications><classifications type="ASJC"><classification>3004</classification><classification>2736</classification></classifications><classifications type="SUBJABBR"><classification>PHAR</classification><classification>MEDI</classification></classifications></classificationgroup></enhancement></head><tail><bibliography refcount="49"><reference id="1"><ref-info><ref-title><ref-titletext>Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.2217/pgs.15.183</itemid><itemid idtype="SGR">84966664007</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>V.</ce:initials><ce:indexed-name>Altmann V.</ce:indexed-name><ce:surname>Altmann</ce:surname></author><author seq="2"><ce:initials>A.F.</ce:initials><ce:indexed-name>Schumacher-Schuh A.F.</ce:indexed-name><ce:surname>Schumacher-Schuh</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Rieck M.</ce:indexed-name><ce:surname>Rieck</ce:surname></author><author seq="4"><ce:initials>S.M.</ce:initials><ce:indexed-name>Callegari-Jacques S.M.</ce:indexed-name><ce:surname>Callegari-Jacques</ce:surname></author><author seq="5"><ce:initials>C.R.</ce:initials><ce:indexed-name>Rieder C.R.</ce:indexed-name><ce:surname>Rieder</ce:surname></author><author seq="6"><ce:initials>M.H.</ce:initials><ce:indexed-name>Hutz M.H.</ce:indexed-name><ce:surname>Hutz</ce:surname></author></ref-authors><ref-sourcetitle>Pharmacogenomics</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="17"/><pagerange first="481" last="488"/></ref-volisspag></ref-info><ref-fulltext>Altmann, V., Schumacher-Schuh, A. F., Rieck, M., Callegari-Jacques, S. M., Rieder, C. R., and Hutz, M. H. (2016). Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease. Pharmacogenomics 17, 481-488. doi: 10.2217/pgs.15.183</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>A reassessment of risks and benefits of dopamine agonists in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/S1474-4422(09)70225-X</itemid><itemid idtype="SGR">69949085340</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Antonini A.</ce:indexed-name><ce:surname>Antonini</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Tolosa E.</ce:indexed-name><ce:surname>Tolosa</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Mizuno Y.</ce:indexed-name><ce:surname>Mizuno</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Yamamoto M.</ce:indexed-name><ce:surname>Yamamoto</ce:surname></author><author seq="5"><ce:initials>W.H.</ce:initials><ce:indexed-name>Poewe W.H.</ce:indexed-name><ce:surname>Poewe</ce:surname></author></ref-authors><ref-sourcetitle>Lancet Neurol.</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="8"/><pagerange first="929" last="937"/></ref-volisspag></ref-info><ref-fulltext>Antonini, A., Tolosa, E., Mizuno, Y., Yamamoto, M., and Poewe, W. H. (2009). A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol. 8, 929-937. doi: 10.1016/S1474-4422(09)70225-X</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1007/s10048-010-0254-5</itemid><itemid idtype="SGR">79951554624</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.L.</ce:initials><ce:indexed-name>Becker M.L.</ce:indexed-name><ce:surname>Becker</ce:surname></author><author seq="2"><ce:initials>L.E.</ce:initials><ce:indexed-name>Visser L.E.</ce:indexed-name><ce:surname>Visser</ce:surname></author><author seq="3"><ce:initials>R.H.</ce:initials><ce:indexed-name>Van Schaik R.H.</ce:indexed-name><ce:surname>Van Schaik</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Hofman A.</ce:indexed-name><ce:surname>Hofman</ce:surname></author><author seq="5"><ce:initials>A.G.</ce:initials><ce:indexed-name>Uitterlinden A.G.</ce:indexed-name><ce:surname>Uitterlinden</ce:surname></author><author seq="6"><ce:initials>B.H.</ce:initials><ce:indexed-name>Stricker B.H.</ce:indexed-name><ce:surname>Stricker</ce:surname></author></ref-authors><ref-sourcetitle>Neurogenetics</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="12"/><pagerange first="79" last="82"/></ref-volisspag></ref-info><ref-fulltext>Becker, M. L., Visser, L. E., van Schaik, R. H., Hofman, A., Uitterlinden, A. G., and Stricker, B. H. (2011). OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 12, 79-82. doi: 10.1007/s10048-010-0254-5</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1097/FPC.0b013e328306c2f2</itemid><itemid idtype="SGR">53049101630</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Bialecka M.</ce:indexed-name><ce:surname>Bialecka</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Kurzawski M.</ce:indexed-name><ce:surname>Kurzawski</ce:surname></author><author seq="3"><ce:initials>G.</ce:initials><ce:indexed-name>Klodowska-Duda G.</ce:indexed-name><ce:surname>Klodowska-Duda</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Opala G.</ce:indexed-name><ce:surname>Opala</ce:surname></author><author seq="5"><ce:initials>E.K.</ce:initials><ce:indexed-name>Tan E.K.</ce:indexed-name><ce:surname>Tan</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Drozdzik M.</ce:indexed-name><ce:surname>Drozdzik</ce:surname></author></ref-authors><ref-sourcetitle>Pharmacogenet. Genomics</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="18"/><pagerange first="815" last="821"/></ref-volisspag></ref-info><ref-fulltext>Bialecka, M., Kurzawski, M., Klodowska-Duda, G., Opala, G., Tan, E. K., and Drozdzik, M. (2008). The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet. Genomics 18, 815-821. doi: 10.1097/FPC.0b013e328306c2f2</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>Adverse events from the treatment of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/j.ncl.2008.05.003</itemid><itemid idtype="SGR">50949128558</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.L.</ce:initials><ce:indexed-name>Chou K.L.</ce:indexed-name><ce:surname>Chou</ce:surname></author></ref-authors><ref-sourcetitle>Neurol. Clin.</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="26"/><pagerange first="S65" last="S83"/></ref-volisspag></ref-info><ref-fulltext>Chou, K. L. (2008). Adverse events from the treatment of Parkinson's disease. Neurol. Clin. 26, S65-83. doi: 10.1016/j.ncl.2008.05.003</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Pharmacological treatment of Parkinson disease: A review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1001/jama.2014.3654</itemid><itemid idtype="SGR">84898775157</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.S.</ce:initials><ce:indexed-name>Connolly B.S.</ce:indexed-name><ce:surname>Connolly</ce:surname></author><author seq="2"><ce:initials>A.E.</ce:initials><ce:indexed-name>Lang A.E.</ce:indexed-name><ce:surname>Lang</ce:surname></author></ref-authors><ref-sourcetitle>JAMA</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="311"/><pagerange first="1670" last="1683"/></ref-volisspag></ref-info><ref-fulltext>Connolly, B. S., and Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670-1683. doi: 10.1001/jama.2014.3654</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1002/mds.23805</itemid><itemid idtype="SGR">84855924547</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.M.</ce:initials><ce:indexed-name>De Lau L.M.</ce:indexed-name><ce:surname>De Lau</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Verbaan D.</ce:indexed-name><ce:surname>Verbaan</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Marinus J.</ce:indexed-name><ce:surname>Marinus</ce:surname></author><author seq="4"><ce:initials>P.</ce:initials><ce:indexed-name>Heutink P.</ce:indexed-name><ce:surname>Heutink</ce:surname></author><author seq="5"><ce:initials>J.J.</ce:initials><ce:indexed-name>Van Hilten J.J.</ce:indexed-name><ce:surname>Van Hilten</ce:surname></author></ref-authors><ref-sourcetitle>Mov. Disord.</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="27"/><pagerange first="132" last="135"/></ref-volisspag></ref-info><ref-fulltext>de Lau, L. M., Verbaan, D., Marinus, J., Heutink, P., and van Hilten, J. J. (2012). Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. Mov. Disord. 27, 132-135. doi: 10.1002/mds.23805</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/j.parkreldis.2013.10.017</itemid><itemid idtype="SGR">84893706207</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Devos D.</ce:indexed-name><ce:surname>Devos</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Lejeune S.</ce:indexed-name><ce:surname>Lejeune</ce:surname></author><author seq="3"><ce:initials>F.</ce:initials><ce:indexed-name>Cormier-Dequaire F.</ce:indexed-name><ce:surname>Cormier-Dequaire</ce:surname></author><author seq="4"><ce:initials>K.</ce:initials><ce:indexed-name>Tahiri K.</ce:indexed-name><ce:surname>Tahiri</ce:surname></author><author seq="5"><ce:initials>F.</ce:initials><ce:indexed-name>Charbonnier-Beaupel F.</ce:indexed-name><ce:surname>Charbonnier-Beaupel</ce:surname></author><author seq="6"><ce:initials>N.</ce:initials><ce:indexed-name>Rouaix N.</ce:indexed-name><ce:surname>Rouaix</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Parkinsonism Relat. Disord.</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="20"/><pagerange first="170" last="175"/></ref-volisspag></ref-info><ref-fulltext>Devos, D., Lejeune, S., Cormier-Dequaire, F., Tahiri, K., Charbonnier-Beaupel, F., Rouaix, N., et al. (2014). Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease. Parkinsonism Relat. Disord. 20, 170-175. doi: 10.1016/j.parkreldis.2013.10.017</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Association of daytime sleepiness with COMT polymorphism in patients with Parkinson disease: A pilot study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1093/sleep/27.4.733</itemid><itemid idtype="SGR">3042536411</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Frauscher B.</ce:indexed-name><ce:surname>Frauscher</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Hogl B.</ce:indexed-name><ce:surname>Högl</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Maret S.</ce:indexed-name><ce:surname>Maret</ce:surname></author><author seq="4"><ce:initials>E.</ce:initials><ce:indexed-name>Wolf E.</ce:indexed-name><ce:surname>Wolf</ce:surname></author><author seq="5"><ce:initials>E.</ce:initials><ce:indexed-name>Brandauer E.</ce:indexed-name><ce:surname>Brandauer</ce:surname></author><author seq="6"><ce:initials>G.K.</ce:initials><ce:indexed-name>Wenning G.K.</ce:indexed-name><ce:surname>Wenning</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Sleep</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="27"/><pagerange first="733" last="736"/></ref-volisspag></ref-info><ref-fulltext>Frauscher, B., Högl, B., Maret, S., Wolf, E., Brandauer, E., Wenning, G. K., et al. (2004). Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study. Sleep 27, 733-736. doi: 10.1093/sleep/27.4.733</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>Genetic variation analysis in Parkinson disease patients with and without hallucinations: Case-control study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1001/archneur.58.2.209</itemid><itemid idtype="SGR">0035112421</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.G.</ce:initials><ce:indexed-name>Goetz C.G.</ce:indexed-name><ce:surname>Goetz</ce:surname></author><author seq="2"><ce:initials>P.F.</ce:initials><ce:indexed-name>Burke P.F.</ce:indexed-name><ce:surname>Burke</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Leurgans S.</ce:indexed-name><ce:surname>Leurgans</ce:surname></author><author seq="4"><ce:initials>E.</ce:initials><ce:indexed-name>Berry-Kravis E.</ce:indexed-name><ce:surname>Berry-Kravis</ce:surname></author><author seq="5"><ce:initials>L.M.</ce:initials><ce:indexed-name>Blasucci L.M.</ce:indexed-name><ce:surname>Blasucci</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Raman R.</ce:indexed-name><ce:surname>Raman</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Arch. Neurol.</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="58"/><pagerange first="209" last="213"/></ref-volisspag></ref-info><ref-fulltext>Goetz, C. G., Burke, P. F., Leurgans, S., Berry-Kravis, E., Blasucci, L. M., Raman, R., et al. (2001). Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch. Neurol. 58, 209-213. doi: 10.1001/archneur.58.2.209</ref-fulltext></reference><reference id="11"><ref-info><refd-itemidlist><itemid idtype="SGR">85065480894</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.G.</ce:initials><ce:indexed-name>Goetz C.G.</ce:indexed-name><ce:surname>Goetz</ce:surname></author><author seq="2"><ce:initials>W.</ce:initials><ce:indexed-name>Poewe W.</ce:indexed-name><ce:surname>Poewe</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Dubois B.</ce:indexed-name><ce:surname>Dubois</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Schrag A.</ce:indexed-name><ce:surname>Schrag</ce:surname></author><author seq="5"><ce:initials>M.B.</ce:initials><ce:indexed-name>Stern M.B.</ce:indexed-name><ce:surname>Stern</ce:surname></author><author seq="6"><ce:initials>A.E.</ce:initials><ce:indexed-name>Lang A.E.</ce:indexed-name><ce:surname>Lang</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>MDS-UPDRS</ref-sourcetitle><ref-publicationyear first="2008"/><ref-website><ce:e-address type="email">http://www.movementdisorders.org/MDS-Files1/PDFs/MDS-UPDRS-Rating-Scales/NewUPDRS7308final.pdf</ce:e-address></ref-website><ref-text>(Accessed Sept 18, 2017).</ref-text></ref-info><ref-fulltext>Goetz, C. G., Poewe, W., Dubois, B., Schrag, A., Stern, M. B., Lang, A. E., et al. (2008). MDS-UPDRS. Available online at: http://www.movementdisorders.org/MDS-Files1/PDFs/MDS-UPDRS-Rating-Scales/NewUPDRS7308final.pdf (Accessed Sept 18, 2017).</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in Parkinson's disease in a Chinese population</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/j.parkreldis.2014.06.021</itemid><itemid idtype="SGR">84908141172</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Hao H.</ce:indexed-name><ce:surname>Hao</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Shao M.</ce:indexed-name><ce:surname>Shao</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>An J.</ce:indexed-name><ce:surname>An</ce:surname></author><author seq="4"><ce:initials>C.</ce:initials><ce:indexed-name>Chen C.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="5"><ce:initials>X.</ce:initials><ce:indexed-name>Feng X.</ce:indexed-name><ce:surname>Feng</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Xie S.</ce:indexed-name><ce:surname>Xie</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Parkinsonism Relat. Disord.</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="20"/><pagerange first="1041" last="1045"/></ref-volisspag></ref-info><ref-fulltext>Hao, H., Shao, M., An, J., Chen, C., Feng, X., Xie, S., et al. (2014). Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population. Parkinsonism Relat. Disord. 20, 1041-1045. doi: 10.1016/j.parkreldis.2014.06.021</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: A PRISMA compliant meta-analysis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.2147/NDT.S118614</itemid><itemid idtype="SGR">85006766696</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>He H.</ce:indexed-name><ce:surname>He</ce:surname></author><author seq="2"><ce:initials>H.</ce:initials><ce:indexed-name>Wu H.</ce:indexed-name><ce:surname>Wu</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Yang L.</ce:indexed-name><ce:surname>Yang</ce:surname></author><author seq="4"><ce:initials>F.</ce:initials><ce:indexed-name>Gao F.</ce:indexed-name><ce:surname>Gao</ce:surname></author><author seq="5"><ce:initials>Y.</ce:initials><ce:indexed-name>Fan Y.</ce:indexed-name><ce:surname>Fan</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Feng J.</ce:indexed-name><ce:surname>Feng</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Neuropsychiatr. Dis. Treat.</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="12"/><pagerange first="3129" last="3144"/></ref-volisspag></ref-info><ref-fulltext>He, H., Wu, H., Yang, L., Gao, F., Fan, Y., Feng, J., et al. (2016). Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis. Neuropsychiatr. Dis. Treat. 12, 3129-3144. doi: 10.2147/NDT.S118614</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>The Role of dopamine and its dysfunction as a consequence of oxidative stress</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1155/2016/9730467</itemid><itemid idtype="SGR">84953309646</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Juarez Olguin H.</ce:indexed-name><ce:surname>Juarez Olguin</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Calderon Guzman D.</ce:indexed-name><ce:surname>Calderon Guzman</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Hernandez Garcia E.</ce:indexed-name><ce:surname>Hernandez Garcia</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Barragan Mejia G.</ce:indexed-name><ce:surname>Barragan Mejia</ce:surname></author></ref-authors><ref-sourcetitle>Oxid. Med. Cell. Longev.</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="2016"/><pagerange first="9730467"/></ref-volisspag></ref-info><ref-fulltext>Juarez Olguin, H., Calderon Guzman, D., Hernandez Garcia, E., and Barragan Mejia, G. (2016). The Role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid. Med. Cell. Longev. 2016:9730467. doi: 10.1155/2016/9730467</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1212/01.WNL.0000068009.32067.A1</itemid><itemid idtype="SGR">0037777723</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Kaiser R.</ce:indexed-name><ce:surname>Kaiser</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Hofer A.</ce:indexed-name><ce:surname>Hofer</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Grapengiesser A.</ce:indexed-name><ce:surname>Grapengiesser</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Gasser T.</ce:indexed-name><ce:surname>Gasser</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Kupsch A.</ce:indexed-name><ce:surname>Kupsch</ce:surname></author><author seq="6"><ce:initials>I.</ce:initials><ce:indexed-name>Roots I.</ce:indexed-name><ce:surname>Roots</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Neurology</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="60"/><pagerange first="1750" last="1755"/></ref-volisspag></ref-info><ref-fulltext>Kaiser, R., Hofer, A., Grapengiesser, A., Gasser, T., Kupsch, A., Roots, I., et al. (2003). L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60, 1750-1755. doi: 10.1212/01.WNL.0000068009.32067.A1</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/S0140-6736(14)61393-3</itemid><itemid idtype="SGR">84940956493</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.V.</ce:initials><ce:indexed-name>Kalia L.V.</ce:indexed-name><ce:surname>Kalia</ce:surname></author><author seq="2"><ce:initials>A.E.</ce:initials><ce:indexed-name>Lang A.E.</ce:indexed-name><ce:surname>Lang</ce:surname></author></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="386"/><pagerange first="896" last="912"/></ref-volisspag></ref-info><ref-fulltext>Kalia, L. V., and Lang, A. E. (2015). Parkinson's disease. Lancet 386, 896-912. doi: 10.1016/S0140-6736(14)61393-3</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>KEGG: Kyoto encyclopedia of genes and genomes</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1093/nar/28.1.27</itemid><itemid idtype="SGR">0033982936</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Kanehisa M.</ce:indexed-name><ce:surname>Kanehisa</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Goto S.</ce:indexed-name><ce:surname>Goto</ce:surname></author></ref-authors><ref-sourcetitle>Nucleic Acids Res.</ref-sourcetitle><ref-publicationyear first="2000"/><ref-volisspag><voliss volume="28"/><pagerange first="27" last="30"/></ref-volisspag></ref-info><ref-fulltext>Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30. doi: 10.1093/nar/28.1.27</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1007/s12031-014-0276-9</itemid><itemid idtype="SGR">84901439384</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Kaplan N.</ce:indexed-name><ce:surname>Kaplan</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Vituri A.</ce:indexed-name><ce:surname>Vituri</ce:surname></author><author seq="3"><ce:initials>A.D.</ce:initials><ce:indexed-name>Korczyn A.D.</ce:indexed-name><ce:surname>Korczyn</ce:surname></author><author seq="4"><ce:initials>O.S.</ce:initials><ce:indexed-name>Cohen O.S.</ce:indexed-name><ce:surname>Cohen</ce:surname></author><author seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Inzelberg R.</ce:indexed-name><ce:surname>Inzelberg</ce:surname></author><author seq="6"><ce:initials>G.</ce:initials><ce:indexed-name>Yahalom G.</ce:indexed-name><ce:surname>Yahalom</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J. Mol. Neurosci.</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="53"/><pagerange first="183" last="188"/></ref-volisspag></ref-info><ref-fulltext>Kaplan, N., Vituri, A., Korczyn, A. D., Cohen, O. S., Inzelberg, R., Yahalom, G., et al. (2014). Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease. J. Mol. Neurosci. 53, 183-188. doi: 10.1007/s12031-014-0276-9</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>Excessive daytime sleepiness in patients with Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.2165/11539720-000000000-00000</itemid><itemid idtype="SGR">79951742216</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Knie B.</ce:indexed-name><ce:surname>Knie</ce:surname></author><author seq="2"><ce:initials>M.T.</ce:initials><ce:indexed-name>Mitra M.T.</ce:indexed-name><ce:surname>Mitra</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Logishetty K.</ce:indexed-name><ce:surname>Logishetty</ce:surname></author><author seq="4"><ce:initials>K.R.</ce:initials><ce:indexed-name>Chaudhuri K.R.</ce:indexed-name><ce:surname>Chaudhuri</ce:surname></author></ref-authors><ref-sourcetitle>CNS Drugs</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="25"/><pagerange first="203" last="212"/></ref-volisspag></ref-info><ref-fulltext>Knie, B., Mitra, M. T., Logishetty, K., and Chaudhuri, K. R. (2011). Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs 25, 203-212. doi: 10.2165/11539720-000000000-00000</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/j.parkreldis.2016.06.005</itemid><itemid idtype="SGR">84977528467</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Krishnamoorthy S.</ce:indexed-name><ce:surname>Krishnamoorthy</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Rajan R.</ce:indexed-name><ce:surname>Rajan</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Banerjee M.</ce:indexed-name><ce:surname>Banerjee</ce:surname></author><author seq="4"><ce:initials>H.</ce:initials><ce:indexed-name>Kumar H.</ce:indexed-name><ce:surname>Kumar</ce:surname></author><author seq="5"><ce:initials>G.</ce:initials><ce:indexed-name>Sarma G.</ce:indexed-name><ce:surname>Sarma</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Krishnan S.</ce:indexed-name><ce:surname>Krishnan</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Parkinsonism Relat. Disord.</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="30"/><pagerange first="13" last="17"/></ref-volisspag></ref-info><ref-fulltext>Krishnamoorthy, S., Rajan, R., Banerjee, M., Kumar, H., Sarma, G., Krishnan, S., et al. (2016). Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. Parkinsonism Relat. Disord. 30, 13-17. doi: 10.1016/j.parkreldis.2016.06.005</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>Improvement in severe orthostatic hypotension following carbidopa dose reduction</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1017/cjn.2017.284</itemid><itemid idtype="SGR">85043275457</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.C.W.</ce:initials><ce:indexed-name>Lau A.C.W.</ce:indexed-name><ce:surname>Lau</ce:surname></author><author seq="2"><ce:initials>J.L.</ce:initials><ce:indexed-name>Diggle J.L.</ce:indexed-name><ce:surname>Diggle</ce:surname></author><author seq="3"><ce:initials>P.P.</ce:initials><ce:indexed-name>Bring P.P.</ce:indexed-name><ce:surname>Bring</ce:surname></author></ref-authors><ref-sourcetitle>Can. J. Neurol. Sci.</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="45"/><pagerange first="252" last="253"/></ref-volisspag></ref-info><ref-fulltext>Lau, A. C. W., Diggle, J. L., and Bring, P. P. (2018). Improvement in severe orthostatic hypotension following carbidopa dose reduction. Can. J. Neurol. Sci. 45, 252-253. doi: 10.1017/cjn.2017.284</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1002/mds.23400</itemid><itemid idtype="SGR">79951485860</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.Y.</ce:initials><ce:indexed-name>Lee J.Y.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Cho J.</ce:indexed-name><ce:surname>Cho</ce:surname></author><author seq="3"><ce:initials>E.K.</ce:initials><ce:indexed-name>Lee E.K.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="4"><ce:initials>S.S.</ce:initials><ce:indexed-name>Park S.S.</ce:indexed-name><ce:surname>Park</ce:surname></author><author seq="5"><ce:initials>B.S.</ce:initials><ce:indexed-name>Jeon B.S.</ce:indexed-name><ce:surname>Jeon</ce:surname></author></ref-authors><ref-sourcetitle>Mov. Disord.</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="26"/><pagerange first="73" last="79"/></ref-volisspag></ref-info><ref-fulltext>Lee, J. Y., Cho, J., Lee, E. K., Park, S. S., and Jeon, B. S. (2011). Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. Mov. Disord. 26, 73-79. doi: 10.1002/mds.23400</ref-fulltext></reference><reference id="23"><ref-info><ref-title><ref-titletext>Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1002/mds.22678</itemid><itemid idtype="SGR">70450044450</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.Y.</ce:initials><ce:indexed-name>Lee J.Y.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="2"><ce:initials>E.K.</ce:initials><ce:indexed-name>Lee E.K.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="3"><ce:initials>S.S.</ce:initials><ce:indexed-name>Park S.S.</ce:indexed-name><ce:surname>Park</ce:surname></author><author seq="4"><ce:initials>J.Y.</ce:initials><ce:indexed-name>Lim J.Y.</ce:indexed-name><ce:surname>Lim</ce:surname></author><author seq="5"><ce:initials>H.J.</ce:initials><ce:indexed-name>Kim H.J.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="6"><ce:initials>J.S.</ce:initials><ce:indexed-name>Kim J.S.</ce:indexed-name><ce:surname>Kim</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Mov. Disord.</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="24"/><pagerange first="1803" last="1810"/></ref-volisspag></ref-info><ref-fulltext>Lee, J. Y., Lee, E. K., Park, S. S., Lim, J. Y., Kim, H. J., Kim, J. S., et al. (2009). Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov. Disord. 24, 1803-1810. doi: 10.1002/mds.22678</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1371/journal.pone.0162866</itemid><itemid idtype="SGR">84992409620</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Mizzi C.</ce:indexed-name><ce:surname>Mizzi</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Dalabira E.</ce:indexed-name><ce:surname>Dalabira</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Kumuthini J.</ce:indexed-name><ce:surname>Kumuthini</ce:surname></author><author seq="4"><ce:initials>N.</ce:initials><ce:indexed-name>Dzimiri N.</ce:indexed-name><ce:surname>Dzimiri</ce:surname></author><author seq="5"><ce:initials>I.</ce:initials><ce:indexed-name>Balogh I.</ce:indexed-name><ce:surname>Balogh</ce:surname></author><author seq="6"><ce:initials>N.</ce:initials><ce:indexed-name>Basak N.</ce:indexed-name><ce:surname>Başak</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>PLoS ONE</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="11"/><pagerange first="e0162866"/></ref-volisspag></ref-info><ref-fulltext>Mizzi, C., Dalabira, E., Kumuthini, J., Dzimiri, N., Balogh, I., Başak, N., et al. (2016). A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS ONE 11:e0162866. doi: 10.1371/journal.pone.0162866</ref-fulltext></reference><reference id="25"><ref-info><ref-title><ref-titletext>Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1093/brain/awv063</itemid><itemid idtype="SGR">84929660509</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Moreau C.</ce:indexed-name><ce:surname>Moreau</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Meguig S.</ce:indexed-name><ce:surname>Meguig</ce:surname></author><author seq="3"><ce:initials>J.C.</ce:initials><ce:indexed-name>Corvol J.C.</ce:indexed-name><ce:surname>Corvol</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Labreuche J.</ce:indexed-name><ce:surname>Labreuche</ce:surname></author><author seq="5"><ce:initials>F.</ce:initials><ce:indexed-name>Vasseur F.</ce:indexed-name><ce:surname>Vasseur</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Duhamel A.</ce:indexed-name><ce:surname>Duhamel</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Brain</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="138"/><pagerange first="1271" last="1283"/></ref-volisspag></ref-info><ref-fulltext>Moreau, C., Meguig, S., Corvol, J. C., Labreuche, J., Vasseur, F., Duhamel, A., et al. (2015). Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. Brain 138, 1271-1283. doi: 10.1093/brain/awv063</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>A review of some aspects of the pharmacology of levodopa</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0018245071</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.G.</ce:initials><ce:indexed-name>Morris J.G.</ce:indexed-name><ce:surname>Morris</ce:surname></author></ref-authors><ref-sourcetitle>Clin. Exp. Neurol.</ref-sourcetitle><ref-publicationyear first="1978"/><ref-volisspag><voliss volume="15"/><pagerange first="24" last="50"/></ref-volisspag></ref-info><ref-fulltext>Morris, J. G. (1978). A review of some aspects of the pharmacology of levodopa. Clin. Exp. Neurol. 15, 24-50.</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>What mechanisms are responsible for the reuptake of levodopa-derived dopamine in parkinsonian striatum?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.3389/fnins.2016.00575</itemid><itemid idtype="SGR">85009789203</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Nishijima H.</ce:indexed-name><ce:surname>Nishijima</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Tomiyama M.</ce:indexed-name><ce:surname>Tomiyama</ce:surname></author></ref-authors><ref-sourcetitle>Front Neurosci.</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="10"/><pagerange first="575"/></ref-volisspag></ref-info><ref-fulltext>Nishijima, H., and Tomiyama, M. (2016). What mechanisms are responsible for the reuptake of levodopa-derived dopamine in parkinsonian striatum? Front. Neurosci. 10:575. doi: 10.3389/fnins.2016.00575</ref-fulltext></reference><reference id="28"><ref-info><ref-title><ref-titletext>Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1002/mds.20134</itemid><itemid idtype="SGR">4444320076</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Paus S.</ce:indexed-name><ce:surname>Paus</ce:surname></author><author seq="2"><ce:initials>G.</ce:initials><ce:indexed-name>Seeger G.</ce:indexed-name><ce:surname>Seeger</ce:surname></author><author seq="3"><ce:initials>H.M.</ce:initials><ce:indexed-name>Brecht H.M.</ce:indexed-name><ce:surname>Brecht</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Koster J.</ce:indexed-name><ce:surname>Koster</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>El-Faddagh M.</ce:indexed-name><ce:surname>El-Faddagh</ce:surname></author><author seq="6"><ce:initials>M.M.</ce:initials><ce:indexed-name>Nothen M.M.</ce:indexed-name><ce:surname>Nöthen</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Mov. Disord.</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="19"/><pagerange first="705" last="707"/></ref-volisspag></ref-info><ref-fulltext>Paus, S., Seeger, G., Brecht, H. M., Koster, J., El-Faddagh, M., Nöthen, M. M., et al. (2004). Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Mov. Disord. 19, 705-707. doi: 10.1002/mds.20134</ref-fulltext></reference><reference id="29"><ref-info><ref-title><ref-titletext>Parkinson disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1038/nrdp.2017.13</itemid><itemid idtype="SGR">85016139358</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.</ce:initials><ce:indexed-name>Poewe W.</ce:indexed-name><ce:surname>Poewe</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Seppi K.</ce:indexed-name><ce:surname>Seppi</ce:surname></author><author seq="3"><ce:initials>C.M.</ce:initials><ce:indexed-name>Tanner C.M.</ce:indexed-name><ce:surname>Tanner</ce:surname></author><author seq="4"><ce:initials>G.M.</ce:initials><ce:indexed-name>Halliday G.M.</ce:indexed-name><ce:surname>Halliday</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Brundin P.</ce:indexed-name><ce:surname>Brundin</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Volkmann J.</ce:indexed-name><ce:surname>Volkmann</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="3"/><pagerange first="17013"/></ref-volisspag></ref-info><ref-fulltext>Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., et al. (2017). Parkinson disease. Nat. Rev. Dis. Primers 3:17013. doi: 10.1038/nrdp.2017.13</ref-fulltext></reference><reference id="30"><ref-info><refd-itemidlist><itemid idtype="SGR">0004121625</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.P.</ce:initials><ce:indexed-name>Rang H.P.</ce:indexed-name><ce:surname>Rang</ce:surname></author><author seq="2"><ce:initials>M.M.</ce:initials><ce:indexed-name>Dale M.M.</ce:indexed-name><ce:surname>Dale</ce:surname></author><author seq="3"><ce:initials>J.M.</ce:initials><ce:indexed-name>Ritter J.M.</ce:indexed-name><ce:surname>Ritter</ce:surname></author><author seq="4"><ce:initials>R.J.</ce:initials><ce:indexed-name>Flower R.J.</ce:indexed-name><ce:surname>Flower</ce:surname></author><author seq="5"><ce:initials>G.</ce:initials><ce:indexed-name>Henderson G.</ce:indexed-name><ce:surname>Henderson</ce:surname></author></ref-authors><ref-sourcetitle>Pharmacology</ref-sourcetitle><ref-publicationyear first="2012"/><ref-text>Edinburgh; London: Churchill Livingstone.</ref-text></ref-info><ref-fulltext>Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J., and Henderson, G. (2012). Pharmacology. Edinburgh; London: Churchill Livingstone.</ref-fulltext></reference><reference id="31"><ref-info><ref-title><ref-titletext>Effects of genetic variability in dopaminergic pathway on treatment response in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85065486283</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Redensek S.</ce:indexed-name><ce:surname>Redenšek</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Trost M.</ce:indexed-name><ce:surname>Trošt</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname></author></ref-authors><ref-sourcetitle>Parkinson's Disease</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><pagerange first="27" last="47"/></ref-volisspag><ref-text>ed S. C. Yenisett (Rijeka: IntechOpen)</ref-text></ref-info><ref-fulltext>Redenšek, S., Trošt, M., and Dolžan, V. (2018). "Effects of genetic variability in dopaminergic pathway on treatment response in Parkinson's disease, " in Parkinson's Disease, ed S. C. Yenisett (Rijeka: IntechOpen), 27-47.</ref-fulltext></reference><reference id="32"><ref-info><ref-title><ref-titletext>Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1038/tpj.2016.79</itemid><itemid idtype="SGR">84992332904</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Rieck M.</ce:indexed-name><ce:surname>Rieck</ce:surname></author><author seq="2"><ce:initials>A.F.</ce:initials><ce:indexed-name>Schumacher-Schuh A.F.</ce:indexed-name><ce:surname>Schumacher-Schuh</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Altmann V.</ce:indexed-name><ce:surname>Altmann</ce:surname></author><author seq="4"><ce:initials>S.M.</ce:initials><ce:indexed-name>Callegari-Jacques S.M.</ce:indexed-name><ce:surname>Callegari-Jacques</ce:surname></author><author seq="5"><ce:initials>C.R.</ce:initials><ce:indexed-name>Rieder C.R.</ce:indexed-name><ce:surname>Rieder</ce:surname></author><author seq="6"><ce:initials>M.H.</ce:initials><ce:indexed-name>Hutz M.H.</ce:indexed-name><ce:surname>Hutz</ce:surname></author></ref-authors><ref-sourcetitle>Pharmacogenomics J.</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="25"/><pagerange first="79"/></ref-volisspag></ref-info><ref-fulltext>Rieck, M., Schumacher-Schuh, A. F., Altmann, V., Callegari-Jacques, S. M., Rieder, C. R., and Hutz, M. H. (2016). Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease. Pharmacogenomics J. 25:79. doi: 10.1038/tpj.2016.79</ref-fulltext></reference><reference id="33"><ref-info><ref-title><ref-titletext>DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.2217/pgs.12.149</itemid><itemid idtype="SGR">84870011434</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Rieck M.</ce:indexed-name><ce:surname>Rieck</ce:surname></author><author seq="2"><ce:initials>A.F.</ce:initials><ce:indexed-name>Schumacher-Schuh A.F.</ce:indexed-name><ce:surname>Schumacher-Schuh</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Altmann V.</ce:indexed-name><ce:surname>Altmann</ce:surname></author><author seq="4"><ce:initials>C.L.</ce:initials><ce:indexed-name>Francisconi C.L.</ce:indexed-name><ce:surname>Francisconi</ce:surname></author><author seq="5"><ce:initials>P.T.</ce:initials><ce:indexed-name>Fagundes P.T.</ce:indexed-name><ce:surname>Fagundes</ce:surname></author><author seq="6"><ce:initials>T.L.</ce:initials><ce:indexed-name>Monte T.L.</ce:indexed-name><ce:surname>Monte</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Pharmacogenomics</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="13"/><pagerange first="1701" last="1710"/></ref-volisspag></ref-info><ref-fulltext>Rieck, M., Schumacher-Schuh, A. F., Altmann, V., Francisconi, C. L., Fagundes, P. T., Monte, T. L., et al. (2012). DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 13, 1701-1710. doi: 10.2217/pgs.12.149</ref-fulltext></reference><reference id="34"><ref-info><ref-title><ref-titletext>Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks"</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1002/mds.20245</itemid><itemid idtype="SGR">8844228229</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>I.</ce:initials><ce:indexed-name>Rissling I.</ce:indexed-name><ce:surname>Rissling</ce:surname></author><author seq="2"><ce:initials>F.</ce:initials><ce:indexed-name>Geller F.</ce:indexed-name><ce:surname>Geller</ce:surname></author><author seq="3"><ce:initials>O.</ce:initials><ce:indexed-name>Bandmann O.</ce:indexed-name><ce:surname>Bandmann</ce:surname></author><author seq="4"><ce:initials>K.</ce:initials><ce:indexed-name>Stiasny-Kolster K.</ce:indexed-name><ce:surname>Stiasny-Kolster</ce:surname></author><author seq="5"><ce:initials>Y.</ce:initials><ce:indexed-name>Korner Y.</ce:indexed-name><ce:surname>Korner</ce:surname></author><author seq="6"><ce:initials>C.</ce:initials><ce:indexed-name>Meindorfner C.</ce:indexed-name><ce:surname>Meindorfner</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Mov. Disord.</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="19"/><pagerange first="1279" last="1284"/></ref-volisspag></ref-info><ref-fulltext>Rissling, I., Geller, F., Bandmann, O., Stiasny-Kolster, K., Korner, Y., Meindorfner, C., et al. (2004). Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks". Mov. Disord. 19, 1279-1284. doi: 10.1002/mds.20245</ref-fulltext></reference><reference id="35"><ref-info><ref-title><ref-titletext>Pharmacology of hallucinations: Several mechanisms for one single symptom?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1155/2014/307106</itemid><itemid idtype="SGR">84903639424</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Rolland B.</ce:indexed-name><ce:surname>Rolland</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Jardri R.</ce:indexed-name><ce:surname>Jardri</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Amad A.</ce:indexed-name><ce:surname>Amad</ce:surname></author><author seq="4"><ce:initials>P.</ce:initials><ce:indexed-name>Thomas P.</ce:indexed-name><ce:surname>Thomas</ce:surname></author><author seq="5"><ce:initials>O.</ce:initials><ce:indexed-name>Cottencin O.</ce:indexed-name><ce:surname>Cottencin</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Bordet R.</ce:indexed-name><ce:surname>Bordet</ce:surname></author></ref-authors><ref-sourcetitle>Biomed Res Int.</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="2014"/><pagerange first="307106"/></ref-volisspag></ref-info><ref-fulltext>Rolland, B., Jardri, R., Amad, A., Thomas, P., Cottencin, O., and Bordet, R. (2014). Pharmacology of hallucinations: several mechanisms for one single symptom? Biomed Res. Int. 2014:307106. doi: 10.1155/2014/307106</ref-fulltext></reference><reference id="36"><ref-info><ref-title><ref-titletext>Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1017/S1461145712001666</itemid><itemid idtype="SGR">84878826892</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.F.</ce:initials><ce:indexed-name>Schumacher-Schuh A.F.</ce:indexed-name><ce:surname>Schumacher-Schuh</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Francisconi C.</ce:indexed-name><ce:surname>Francisconi</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Altmann V.</ce:indexed-name><ce:surname>Altmann</ce:surname></author><author seq="4"><ce:initials>T.L.</ce:initials><ce:indexed-name>Monte T.L.</ce:indexed-name><ce:surname>Monte</ce:surname></author><author seq="5"><ce:initials>S.M.</ce:initials><ce:indexed-name>Callegari-Jacques S.M.</ce:indexed-name><ce:surname>Callegari-Jacques</ce:surname></author><author seq="6"><ce:initials>C.R.</ce:initials><ce:indexed-name>Rieder C.R.</ce:indexed-name><ce:surname>Rieder</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Int. J. Neuropsychopharmacol.</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="16"/><pagerange first="1251" last="1258"/></ref-volisspag></ref-info><ref-fulltext>Schumacher-Schuh, A. F., Francisconi, C., Altmann, V., Monte, T. L., Callegari-Jacques, S. M., Rieder, C. R., et al. (2013). Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. Int. J. Neuropsychopharmacol. 16, 1251-1258. doi: 10.1017/S1461145712001666</ref-fulltext></reference><reference id="37"><ref-info><ref-title><ref-titletext>DbSNP: The NCBI database of genetic variation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1093/nar/29.1.308</itemid><itemid idtype="SGR">0035173378</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.T.</ce:initials><ce:indexed-name>Sherry S.T.</ce:indexed-name><ce:surname>Sherry</ce:surname></author><author seq="2"><ce:initials>M.H.</ce:initials><ce:indexed-name>Ward M.H.</ce:indexed-name><ce:surname>Ward</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Kholodov M.</ce:indexed-name><ce:surname>Kholodov</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Baker J.</ce:indexed-name><ce:surname>Baker</ce:surname></author><author seq="5"><ce:initials>L.</ce:initials><ce:indexed-name>Phan L.</ce:indexed-name><ce:surname>Phan</ce:surname></author><author seq="6"><ce:initials>E.M.</ce:initials><ce:indexed-name>Smigielski E.M.</ce:indexed-name><ce:surname>Smigielski</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Nucleic Acids Res.</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="29"/><pagerange first="308" last="311"/></ref-volisspag></ref-info><ref-fulltext>Sherry, S. T., Ward, M. H., Kholodov, M., Baker, J., Phan, L., Smigielski, E. M., et al. (2001). dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311. doi: 10.1093/nar/29.1.308</ref-fulltext></reference><reference id="38"><ref-info><ref-title><ref-titletext>Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1002/mds.20785</itemid><itemid idtype="SGR">33646945878</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.A.</ce:initials><ce:indexed-name>Strong J.A.</ce:indexed-name><ce:surname>Strong</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Dalvi A.</ce:indexed-name><ce:surname>Dalvi</ce:surname></author><author seq="3"><ce:initials>F.J.</ce:initials><ce:indexed-name>Revilla F.J.</ce:indexed-name><ce:surname>Revilla</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Sahay A.</ce:indexed-name><ce:surname>Sahay</ce:surname></author><author seq="5"><ce:initials>F.J.</ce:initials><ce:indexed-name>Samaha F.J.</ce:indexed-name><ce:surname>Samaha</ce:surname></author><author seq="6"><ce:initials>J.A.</ce:initials><ce:indexed-name>Welge J.A.</ce:indexed-name><ce:surname>Welge</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Mov. Disord.</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="21"/><pagerange first="654" last="659"/></ref-volisspag></ref-info><ref-fulltext>Strong, J. A., Dalvi, A., Revilla, F. J., Sahay, A., Samaha, F. J., Welge, J. A., et al. (2006). Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 21, 654-659. doi: 10.1002/mds.20785</ref-fulltext></reference><reference id="39"><ref-info><ref-title><ref-titletext>Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84978858033</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Terzic T.</ce:indexed-name><ce:surname>Terzić</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Kastelic M.</ce:indexed-name><ce:surname>Kastelic</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname></author><author seq="4"><ce:initials>B.K.</ce:initials><ce:indexed-name>Plesnicar B.K.</ce:indexed-name><ce:surname>Plesnicar</ce:surname></author></ref-authors><ref-sourcetitle>Psychiatr. Danub.</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="28"/><pagerange first="127" last="131"/></ref-volisspag></ref-info><ref-fulltext>Terzić, T., Kastelic, M., Dolžan, V., and Plesnicar, B. K. (2016). Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia. Psychiatr. Danub. 28, 127-131.</ref-fulltext></reference><reference id="40"><ref-info><ref-title><ref-titletext>Systematic review of levodopa dose equivalency reporting in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1002/mds.23429</itemid><itemid idtype="SGR">78349261173</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.L.</ce:initials><ce:indexed-name>Tomlinson C.L.</ce:indexed-name><ce:surname>Tomlinson</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Stowe R.</ce:indexed-name><ce:surname>Stowe</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Patel S.</ce:indexed-name><ce:surname>Patel</ce:surname></author><author seq="4"><ce:initials>C.</ce:initials><ce:indexed-name>Rick C.</ce:indexed-name><ce:surname>Rick</ce:surname></author><author seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Gray R.</ce:indexed-name><ce:surname>Gray</ce:surname></author><author seq="6"><ce:initials>C.E.</ce:initials><ce:indexed-name>Clarke C.E.</ce:indexed-name><ce:surname>Clarke</ce:surname></author></ref-authors><ref-sourcetitle>Mov. Disord.</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="25"/><pagerange first="2649" last="2653"/></ref-volisspag></ref-info><ref-fulltext>Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., and Clarke, C. E. (2010). Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 25, 2649-2653. doi: 10.1002/mds.23429</ref-fulltext></reference><reference id="41"><ref-info><ref-title><ref-titletext>A new Java interface implementation of THESIAS: Testing haplotype effects in association studies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1093/bioinformatics/btm058</itemid><itemid idtype="SGR">34249662218</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.A.</ce:initials><ce:indexed-name>Tregouet D.A.</ce:indexed-name><ce:surname>Tregouet</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Garelle V.</ce:indexed-name><ce:surname>Garelle</ce:surname></author></ref-authors><ref-sourcetitle>Bioinformatics</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="23"/><pagerange first="1038" last="1039"/></ref-volisspag></ref-info><ref-fulltext>Tregouet, D. A., and Garelle, V. (2007). A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 23, 1038-1039. doi: 10.1093/bioinformatics/btm058</ref-fulltext></reference><reference id="42"><ref-info><refd-itemidlist><itemid idtype="SGR">84947023158</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.J.B.</ce:initials><ce:indexed-name>Vidan-Jeras B.J.B.</ce:indexed-name><ce:surname>Vidan-Jeras</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Dolzan V.</ce:indexed-name><ce:surname>Dolžan</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Jeras M.</ce:indexed-name><ce:surname>Jeras</ce:surname></author><author seq="4"><ce:initials>K.</ce:initials><ce:indexed-name>Breskvar K.</ce:indexed-name><ce:surname>Breskvar</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Bohinjec M.</ce:indexed-name><ce:surname>Bohinjec</ce:surname></author></ref-authors><ref-sourcetitle>Slovenian Caucasian Normal.</ref-sourcetitle><ref-publicationyear first="1998"/><ref-text>Kansas: HLA.</ref-text></ref-info><ref-fulltext>Vidan-Jeras, B. J. B., Dolžan, V., Jeras, M., Breskvar, K., and Bohinjec, M. (1998). Slovenian Caucasian Normal. Kansas: HLA.</ref-fulltext></reference><reference id="43"><ref-info><ref-title><ref-titletext>Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1159/000074637</itemid><itemid idtype="SGR">0346749729</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Watanabe M.</ce:indexed-name><ce:surname>Watanabe</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Harada S.</ce:indexed-name><ce:surname>Harada</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Nakamura T.</ce:indexed-name><ce:surname>Nakamura</ce:surname></author><author seq="4"><ce:initials>N.</ce:initials><ce:indexed-name>Ohkoshi N.</ce:indexed-name><ce:surname>Ohkoshi</ce:surname></author><author seq="5"><ce:initials>K.</ce:initials><ce:indexed-name>Yoshizawa K.</ce:indexed-name><ce:surname>Yoshizawa</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Hayashi A.</ce:indexed-name><ce:surname>Hayashi</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Neuropsychobiology</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="48"/><pagerange first="190" last="193"/></ref-volisspag></ref-info><ref-fulltext>Watanabe, M., Harada, S., Nakamura, T., Ohkoshi, N., Yoshizawa, K., Hayashi, A., et al. (2003). Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 48, 190-193. doi: 10.1159/000074637</ref-fulltext></reference><reference id="44"><ref-info><ref-title><ref-titletext>Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.2165/11318330-000000000-00000</itemid><itemid idtype="SGR">77950669992</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.D.</ce:initials><ce:indexed-name>Wood L.D.</ce:indexed-name><ce:surname>Wood</ce:surname></author></ref-authors><ref-sourcetitle>Drugs Aging</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="27"/><pagerange first="295" last="310"/></ref-volisspag></ref-info><ref-fulltext>Wood, L. D. (2010). Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging 27, 295-310. doi: 10.2165/11318330-000000000-00000</ref-fulltext></reference><reference id="45"><ref-info><ref-title><ref-titletext>Catechol-O-methyltransferase Val158Met polymorphism: Modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1016/j.parkreldis.2014.07.011</itemid><itemid idtype="SGR">84908127934</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Wu H.</ce:indexed-name><ce:surname>Wu</ce:surname></author><author seq="2"><ce:initials>F.</ce:initials><ce:indexed-name>Dong F.</ce:indexed-name><ce:surname>Dong</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Wang Y.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="4"><ce:initials>Q.</ce:initials><ce:indexed-name>Xiao Q.</ce:indexed-name><ce:surname>Xiao</ce:surname></author><author seq="5"><ce:initials>Q.</ce:initials><ce:indexed-name>Yang Q.</ce:indexed-name><ce:surname>Yang</ce:surname></author><author seq="6"><ce:initials>J.</ce:initials><ce:indexed-name>Zhao J.</ce:indexed-name><ce:surname>Zhao</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Parkinsonism Relat. Disord.</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="20"/><pagerange first="1094" last="1096"/></ref-volisspag></ref-info><ref-fulltext>Wu, H., Dong, F., Wang, Y., Xiao, Q., Yang, Q., Zhao, J., et al. (2014). Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's disease. Parkinsonism Relat. Disord. 20, 1094-1096. doi: 10.1016/j.parkreldis.2014.07.011</ref-fulltext></reference><reference id="46"><ref-info><ref-title><ref-titletext>SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1093/nar/gkp290</itemid><itemid idtype="SGR">67849101182</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Z.</ce:initials><ce:indexed-name>Xu Z.</ce:indexed-name><ce:surname>Xu</ce:surname></author><author seq="2"><ce:initials>J.A.</ce:initials><ce:indexed-name>Taylor J.A.</ce:indexed-name><ce:surname>Taylor</ce:surname></author></ref-authors><ref-sourcetitle>Nucleic Acids Res.</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="37"/><pagerange first="W600" last="W605"/></ref-volisspag></ref-info><ref-fulltext>Xu, Z., and Taylor, J. A. (2009). SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 37, W600-5. doi: 10.1093/nar/gkp290</ref-fulltext></reference><reference id="47"><ref-info><ref-title><ref-titletext>Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1007/s00441-018-2813-2</itemid><itemid idtype="SGR">85042906703</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>You H.</ce:indexed-name><ce:surname>You</ce:surname></author><author seq="2"><ce:initials>L.L.</ce:initials><ce:indexed-name>Mariani L.L.</ce:indexed-name><ce:surname>Mariani</ce:surname></author><author seq="3"><ce:initials>G.</ce:initials><ce:indexed-name>Mangone G.</ce:indexed-name><ce:surname>Mangone</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Le Febvre De Nailly D.</ce:indexed-name><ce:surname>Le Febvre De Nailly</ce:surname></author><author seq="5"><ce:initials>F.</ce:initials><ce:indexed-name>Charbonnier-Beaupel F.</ce:indexed-name><ce:surname>Charbonnier-Beaupel</ce:surname></author><author seq="6"><ce:initials>J.C.</ce:initials><ce:indexed-name>Corvol J.C.</ce:indexed-name><ce:surname>Corvol</ce:surname></author></ref-authors><ref-sourcetitle>Cell Tissue Res.</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="373"/><pagerange first="111" last="135"/></ref-volisspag></ref-info><ref-fulltext>You, H., Mariani, L. L., Mangone, G., Le Febvre de Nailly, D., Charbonnier-Beaupel, F., and Corvol, J. C. (2018). Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. Cell Tissue Res. 373, 111-135. doi: 10.1007/s00441-018-2813-2</ref-fulltext></reference><reference id="48"><ref-info><ref-title><ref-titletext>DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1186/s12883-015-0316-2</itemid><itemid idtype="SGR">84928604251</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Zainal Abidin S.</ce:indexed-name><ce:surname>Zainal Abidin</ce:surname></author><author seq="2"><ce:initials>E.L.</ce:initials><ce:indexed-name>Tan E.L.</ce:indexed-name><ce:surname>Tan</ce:surname></author><author seq="3"><ce:initials>S.C.</ce:initials><ce:indexed-name>Chan S.C.</ce:indexed-name><ce:surname>Chan</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Jaafar A.</ce:indexed-name><ce:surname>Jaafar</ce:surname></author><author seq="5"><ce:initials>A.X.</ce:initials><ce:indexed-name>Lee A.X.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="6"><ce:initials>M.H.</ce:initials><ce:indexed-name>Abd Hamid M.H.</ce:indexed-name><ce:surname>Abd Hamid</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>BMC Neurol.</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="15"/><pagerange first="59"/></ref-volisspag></ref-info><ref-fulltext>Zainal Abidin, S., Tan, E. L., Chan, S. C., Jaafar, A., Lee, A. X., Abd Hamid, M. H., et al. (2015). DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients. BMC Neurol. 15:59. doi: 10.1186/s12883-015-0316-2</ref-fulltext></reference><reference id="49"><ref-info><ref-title><ref-titletext>Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: An exploratory study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="DOI">10.1001/archneur.62.4.601</itemid><itemid idtype="SGR">20144388439</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Zappia M.</ce:indexed-name><ce:surname>Zappia</ce:surname></author><author seq="2"><ce:initials>G.</ce:initials><ce:indexed-name>Annesi G.</ce:indexed-name><ce:surname>Annesi</ce:surname></author><author seq="3"><ce:initials>G.</ce:initials><ce:indexed-name>Nicoletti G.</ce:indexed-name><ce:surname>Nicoletti</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Arabia G.</ce:indexed-name><ce:surname>Arabia</ce:surname></author><author seq="5"><ce:initials>F.</ce:initials><ce:indexed-name>Annesi F.</ce:indexed-name><ce:surname>Annesi</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Messina D.</ce:indexed-name><ce:surname>Messina</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Arch. Neurol.</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="62"/><pagerange first="601" last="605"/></ref-volisspag></ref-info><ref-fulltext>Zappia, M., Annesi, G., Nicoletti, G., Arabia, G., Annesi, F., Messina, D., et al. (2005). Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch. Neurol. 62, 601-605. doi: 10.1001/archneur.62.4.601</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>